National Hospital Organization Asahikawa Medical Center

Alternate names: Asahikawa Medical Center, 国立病院機構旭川医療センター, 旭川医療センター

Parent institution: National Hospital Organization

ROR: 0365fca61

OpenAlex ID: I4405284222

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

2019 · Haruhiro Saito, Tatsuro Fukuhara, et al. · The Lancet Oncology · 638

Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)

2012 · A. Inoue, K. Kobayashi, et al. · Annals of Oncology · 546

Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study

2019 · Yukio Hosomi, Satoshi Morita, et al. · Journal of Clinical Oncology · 491

Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention

2018 · Davide Capodanno, Roxana Mehran, et al. · Nature Reviews Cardiology · 223

Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial

2021 · Yosuke Kawashima, Tatsuro Fukuhara, et al. · The Lancet Respiratory Medicine · 150

Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009).

2018 · Atsushi Nakamura, Akira Inoue, et al. · Journal of Clinical Oncology · 112

Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902

2015 · S. Sugawara, S. Oizumi, et al. · Annals of Oncology · 109

Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR

2022 · Eisaku Miyauchi, Satoshi Morita, et al. · Journal of Clinical Oncology · 104

PDF

Myotonic dystrophy CTG expansion affects synaptic vesicle proteins, neurotransmission and mouse behaviour

2013 · Oscar Hernández-Hernández, Céline Guiraud-Dogan, et al. · Brain · 86

Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non–Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial

2020 · Isamu Okamoto, Hiroshi Nokihara, et al. · JAMA Oncology · 71

Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702)

2019 · Megumi Furuta, Jun Sakakibara-Konishi, et al. · The Oncologist · 66

Clinicopathologic Features of Oculopharyngodistal Myopathy WithLRP12CGG Repeat Expansions Compared With Other Oculopharyngodistal Myopathy Subtypes

2021 · Theerawat Kumutpongpanich, Masashi Ogasawara, et al. · JAMA Neurology · 56

PDF

Alectinib for Patients with ALK Rearrangement–Positive Non–Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401)

2017 · Eiji Iwama, Yasushi Goto, et al. · Journal of Thoracic Oncology · 52

Kallikrein 6 secreted by oligodendrocytes regulates the progression of experimental autoimmune encephalomyelitis

2017 · Yoshio Bando, Yoshiaki Hagiwara, et al. · Glia · 51

A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302)

2019 · Hajime Asahina, Satoshi Oizumi, et al. · Lung Cancer · 50

PDF

A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A

2016 · Kazuhiro Usui, Shunichi Sugawara, et al. · Lung Cancer · 48

Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations

2018 · Satoshi Oizumi, Shunichi Sugawara, et al. · ESMO Open · 42

Deficient RNA-editing enzyme ADAR2 in an amyotrophic lateral sclerosis patient with a FUSP525L mutation

2016 · Hitoshi Aizawa, Takuto Hideyama, et al. · Journal of Clinical Neuroscience · 41

Impaired Nucleoporins Are Present in Sporadic Amyotrophic Lateral Sclerosis Motor Neurons that Exhibit Mislocalization of the 43-kDa TAR DNA-Binding Protein

2019 · Hitoshi Aizawa, Takenari Yamashita, et al. · Journal of Clinical Neurology · 38

PDF

Effectiveness of Oral Iron Chelator Treatment with Deferasirox in an Aceruloplasminemia Patient with a Novel Ceruloplasmin Gene Mutation

2013 · Yasuhiro Suzuki, Kosuke Yoshida, et al. · Internal Medicine · 36

PDF

Selection of Oral Antifungals for Initial Maintenance Therapy in Chronic Pulmonary Aspergillosis: A Longitudinal Analysis

2019 · Masato Tashiro, Takahiro Takazono, et al. · Clinical Infectious Diseases · 35

Allergic bronchopulmonary aspergillosis with atopic, nonatopic, and sans asthma—Factor analysis

2023 · Naoki Okada, Yoshiro Yamamoto, et al. · Allergy · 32

PDF

Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study

2020 · Tatsuro Fukuhara, Haruhiro Saito, et al. · EBioMedicine · 32

PDF

Safety and efficacy of first‐line dacomitinib in Japanese patients with advanced non‐small cell lung cancer

2020 · Makoto Nishio, Terufumi Kato, et al. · Cancer Science · 32

Risk Factors for Delayed Bleeding after Therapeutic Gastrointestinal Endoscopy in Patients Receiving Oral Anticoagulants: A Multicenter Retrospective Study

2019 · Kimitoshi Kubo, Mototsugu Kato, et al. · Digestion · 31

Works count: 235

Citation count: 5,839